Overview

Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
This study aims to assess the tolerability of duloxetine, 60mg once daily, in open label fashion, in depressed patients with Parkinson's disease during 12 weeks treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Duloxetine Hydrochloride